Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Overview of attention for article published in Nature Cancer, April 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

blogs: 1 blog
twitter: 11 X users

guideline: 1 clinical guideline source
bluesky: 2 Bluesky users

Readers on

mendeley: 36 Mendeley

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 93,910 followers.

RT @majorajay: Glofi escalated ramp-up post-CAR: - glofi 30 mg by D8 - 46 pts, all prior CAR, 48% relapse >6 mos post CAR - mPFS 3.8 mos, m…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.